Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial-Reference-Cited by-同舟云学术

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial

Published:2020-04 Issue:4 Volume:7 Page:e309-e319
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Stein Eytan M,Fathi Amir T,DiNardo Courtney D,Pollyea Daniel A,Roboz Gail J,Collins Robert,Sekeres Mikkael A,Stone Richard M,Attar Eyal C,Frattini Mark G,Tosolini Alessandra,Xu Qiang,See Wendy L,MacBeth Kyle J,de Botton Stéphane,Tallman Martin S,Kantarjian Hagop M

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Myelodysplastic syndromes;Tefferi;N Engl J Med,2009

2. Molecular data and the IPSS-R: how mutational burden can affect prognostication in MDS;Nazha;Curr Hematol Malig Rep,2017

3. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease;Visconte;Blood Res,2014

4. Somatic mutations precede acute myeloid leukemia years before diagnosis;Desai;Nat Med,2018

5. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression;DiNardo;Leukemia,2016

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture‐Based Gene Panel;Genes, Chromosomes and Cancer;2024-07

2. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes;Biomedicine & Pharmacotherapy;2024-06

3. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials;Blood Advances;2024-05-21

4. The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies;Frontiers in Oncology;2024-05-10

5. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07